Marcella Origgi (PhD) is the Chief Executive Officer of Valo Therapeutics. She brings extensive experience across immunology, oncohematology, rare inherited diseases, precision medicine and advanced therapy medicinal products (ATMPs).
Marcella Origgi (PhD) is the Chief Executive Officer of Valo Therapeutics. She brings extensive experience across immunology, oncohematology, rare inherited diseases, precision medicine and advanced therapy medicinal products (ATMPs).
Dr Andrew Dean, Board Member, completed his medical training in the UK, became a fellow of the Royal Australian College of Physicians in 1993. He established the palliative care services at Sir Charles Gairdner Hospital and St John of God Subiaco in Perth, later becoming professor of palliative medicine at Edith Cowan University Western Australia.
Dr Harri Järveläinen, Chief Operating Officer, is a pharma industry veteran with a track record of more than 50 development programs – leading preclinical and clinical development, manufacturing, business development, fundraising, and project management. Over the past 20 years, he has held various progressively senior-level roles at large companies such as AstraZeneca, Nestlé, and Pharmaron. Harri Järveläinen has also actively and successfully built and operated several early-stage biotech companies, guiding them from inception to clinical milestones.
Kalle Manninen, Technical Scientist, holds an M.Sc. in Pharmacy from the University of Helsinki with a major in Biopharmacy. During his studies he was chosen to the researcher line in the Faculty of Pharmacy, so he has worked as a Research Assistant in several research projects, where most of his professional time was used on utilizing Surface plasmon resonance and Raman spectroscopy in characterization of extracellular vesicles and polymer brushes.
Please be aware that fraudulent messages related to the ValoTx recruitment processes have been circulating. Do not engage with these advertisements.
Philip Stanecki, Accounting Manager, holds an M.Sc in Economics and Business Administration (International Business) from Copenhagen Business School. Before joining the Valo Therapeutics team as an Accounting Manager, he worked as an accountant at a licensed accounting office, as well as an auditor at a Big 4 firm in Helsinki. He has been working with listed and large non-listed audit clients over the past few years from a broad range of industries.
Sandeep Kumar, Research Scientist II, holds a PhD degree in Biochemistry and his academic
research work was focused on drug discovery. He authored several research articles,
reviews and book chapters in peer reviewed journals. After graduation in 2019, he served as
an Assistant Professor of Biochemistry in veterinary research institute in India. In 2020, he
joined as a Research Scientist in Clinical Science department of Targovax, a clinical stage
immuno-oncology company. He was responsible for planning and execution of preclinical
Suvi Karumo, Laboratory Scientist, holds an M.Sc in Pharmacy from the University of Helsinki with a major in Biopharmacy. Before joining Valo Therapeutics as a Laboratory Scientist in Antigen Business Unit, she has worked as a Research Assistant and Project Researcher in Drug Delivery Group of the University of Helsinki.
Joseph Ndika, Senior Scientist, Antigen Analytics holds a PhD in Clinical Chemistry from Vrije University Medical Center, Amsterdam, Netherlands. Dr Ndika has over 14 years of experience using proteomics (mass spectrometry) and transcriptomics (next generation sequencing, microarrays) profiling of clinical samples to; study perturbation of biological pathways in rare genetic disorders, unravel allergic disease mechanisms and identify diagnostic biomarkers of adverse environmental exposures.